Neurocrine Biosciences Inc (NAS:NBIX)
$ 136.53 -0.46 (-0.34%) Market Cap: 13.82 Bil Enterprise Value: 12.85 Bil PE Ratio: 36.60 PB Ratio: 5.08 GF Score: 88/100

Neurocrine Biosciences Inc at Jefferies London Healthcare Conference Transcript

Nov 15, 2022 / 01:30PM GMT
Release Date Price: $114.77 (-2.78%)
Akash Tewari
Jefferies LLC, Research Division - Equity Analyst

London Healthcare Conference. Really enjoying it so far. I have the pleasure of hosting Neurocrine. With us, we have -- by the way, my name is Akash Tewari. I'm one of the biotech analysts here at Jefferies. Today, I have the pleasure of hosting Neurocrine. Joining us today is Kevin Gorman, CEO; Matthew Abernethy, CFO; and then finally, Kyle Gano, Chief BD and Strategy Officer. Obviously, Neurocrine has been a huge winner for investors this year. How much are you guys up 40%? Something really impressive performers versus the market.

And then I think for investors, it's interesting. I was sitting next to a long only. And they said, Akash, the way that health care investors look at the stock and the way that general slip to stock are totally different. We're always worried about what's going on in 2028, 2030 and all these kind of unknowable debates, what generalist tells me is, Akash, this company has 30% to 40% revenue and EPS acceleration. The PEG is too cheap. And I can't find companies like that in my portfolio. And that's what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot